Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

[Effect of imatinib treatment of gastrointestinal stromal tumors].

Eckhardt S, Pápai Z, Bodoky G, Horti J, Tamás K, Nagy T, Orosz Z, Sápi Z, Gödény M, Jakab K, Esik O, Trón L, Besznyák I.

Orv Hetil. 2003 Nov 9;144(45):2207-12. Hungarian.

PMID:
14686005
2.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R.

Clin Cancer Res. 2002 Oct;8(10):3034-8.

3.

Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.

Kanda T, Ishikawa T, Hirota S, Yajima K, Kosugi S, Ohashi M, Suzuki S, Mashima Y, Ajioka Y, Hatakeyama K.

Jpn J Clin Oncol. 2012 Jul;42(7):578-85. doi: 10.1093/jjco/hys056. Epub 2012 Apr 21.

PMID:
22523393
4.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.

N Engl J Med. 2002 Aug 15;347(7):472-80.

5.

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY; French Sarcoma Group.

Lancet Oncol. 2010 Oct;11(10):942-9. doi: 10.1016/S1470-2045(10)70222-9. Epub 2010 Sep 21.

PMID:
20864406
6.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Lancet. 2001 Oct 27;358(9291):1421-3.

PMID:
11705489
7.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
8.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
9.

Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.

Hasan S, Hassan M, Oke L, Dinh K, Onojobi G, Lombardo F, Dawkins F, Jack M.

J Natl Med Assoc. 2003 Dec;95(12):1208-10.

10.

The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).

Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, Dudek K, Krawczyk M, Ruka W.

Neoplasma. 2003;50(6):438-42.

PMID:
14689066
11.

[18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].

Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.

Rev Esp Med Nucl. 2008 May-Jun;27(3):168-75. Spanish.

12.

Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.

Durosinmi MA, Salawu L, Lawal OO, Ojo OS, Alatishe OI, Oyekunle AA, Bolarinwa RA, Adisa AO, Badmos K, Anomneze EE, Ayansanwo AO.

Afr J Med Med Sci. 2013 Dec;42(4):325-32.

PMID:
24839736
13.

Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.

Schindler CG, Armbrust T, Gunawan B, Langer C, Füzesi L, Ramadori G.

Z Gastroenterol. 2005 Mar;43(3):267-73.

PMID:
15765299
14.

F-18 FDG PET imaging in gastrointestinal stromal tumor.

Reddy MP, Reddy P, Lilien DL.

Clin Nucl Med. 2003 Aug;28(8):677-9.

PMID:
12897659
15.

Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.

Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, Bonenkamp JJ, van der Graaf WT, de Wilt JH.

Eur J Surg Oncol. 2013 Feb;39(2):150-5. doi: 10.1016/j.ejso.2012.09.004. Epub 2012 Oct 16.

16.

Gastrointestinal stromal tumors: chemotherapy and imatinib.

Muler JH, Baker L, Zalupski MM.

Curr Oncol Rep. 2002 Nov;4(6):499-503. Review.

PMID:
12354362
17.

[Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].

Larsen JB.

Ugeskr Laeger. 2003 Sep 8;165(37):3503-7. Review. Danish.

PMID:
14531349
18.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.

Eur J Cancer. 2014 Jul;50(10):1772-8. doi: 10.1016/j.ejca.2014.03.280. Epub 2014 Apr 22.

PMID:
24768330
19.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

20.

Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.

Joensuu H.

Drugs. 2012 Oct 22;72(15):1953-63. doi: 10.2165/11635590-000000000-00000.

PMID:
22994537

Supplemental Content

Support Center